Adn-388

-arrestin causes receptors to "internalize" or become desensitized over time. By avoiding this, CT-388 aims for prolonged pharmacological activity and potentially more durable weight loss.

As of early 2026, CT-388 has demonstrated some of the highest weight-loss percentages recorded in the incretin class. ADN-388

is a potent investigational weight-loss drug currently in Phase III clinical development. Developed by Roche and its subsidiary Genentech, this once-weekly subcutaneous injection belongs to the "incretin mimetic" class, similar to popular medications like Wegovy and Zepbound. Core Mechanism: How CT-388 Works ADN-388